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In observational studies, treatment is often time dependent.
Mishandling the time from the beginning of follow-up
to treatment initiation can result in bias known as
immortal time bias. Nephrology researchers who conduct
observational research must be aware of how immortal time
bias can be introduced into analyses. We review immortal
time bias issues in time-to-event analyses in the biomedical
literature and give examples from the nephrology literature.
We also use simulations to quantify the bias in different
methods of mishandling immortal time; intuitively explain
how bias is introduced when immortal time is mishandled;
raise issues regarding unadjusted treatment comparison,
patient characteristics comparison, and confounder
adjustment; and, using data from DaVita Inc., linked with the
Centers for Medicare & Medicaid Services end-stage renal
disease database, show that the severity of bias and the
issues described can occur in actual data analyses of patients
with end-stage renal disease. In the simulation examples,
mishandling immortal time led to an underestimated
hazard ratio (treatment vs. control), thus an overestimated
treatment effect, by as much as 96%, and an overestimated
hazard ratio by as much as 138%, depending on the
distribution of ‘survival’ time and the method used. Results
from the DaVita data were consistent with the simulation.
Careful consideration of methodology is needed in
observational analyses with time-dependent treatment.
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In observational studies, medical, surgical, or pharmaceutical
treatment is often time dependent. Specifically, treatment for
some patients may not begin at the beginning of the
designated follow-up period, but at a later time. For example,
to compare survival of end-stage renal disease (ESRD)
patients who undergo hemodialysis or kidney transplant,
patients are followed up from the date of registration on the
transplant waiting list. Kidney transplant is a time-dependent
treatment. Some patients may undergo transplant at the
beginning of follow-up, others may never undergo trans-
plant, and still others may undergo transplant after the
beginning of follow-up. This time-dependent feature should
be considered in analyses, or treatment effect estimates may
be biased. The key to avoiding biased estimates is proper
handling of the time from the beginning of follow-up to
treatment initiation, a time during which no study event
occurs. In epidemiological studies, this period is known as
immortal time. Immortal time occurs only for patients who
initiate treatment after the beginning of follow-up (Figure 1).
In this article, we review issues related to immortal time bias
as depicted in the biomedical literature, provide simulations
to help describe the potential size of the bias for different
methods of mishandling immortal time, explain how bias
was introduced by each method, and offer suggestions
regarding how to avoid introducing immortal time bias into
analyses, as well as raise other issues, including patient
characteristics comparison and unadjusted treatment effect
assessment. In addition, we offer an example from ESRD
patient data to show that the severity of bias and the issues
described are not only theoretically possible but actually
occur. The software used for analysis in this study was SAS
v9.1 (SAS Institute, Cary, NC).
RECOGNITION OF IMMORTAL TIME BIAS IN BIOMEDICAL AND
NEPHROLOGY LITERATURE
Immortal time bias was first identified by Gail1 in the 1970s
in two observational studies evaluating survival after heart
transplant,2,3 and was corrected by Mantel and Byar4 in a
reanalysis. Immortal time is frequently mishandled. Van
Walraven et al.5 reviewed 127 studies with time-dependent
variables published in leading clinical journals, and found
that in 52, researchers mishandled immortal time. Of these,
35 studies used the time-dependent variable as the primary
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variable. Immortal time can be mishandled in different ways:
misclassification (considering patients as treated in the
immortal time period) or exclusion (following treated
patients from treatment initiation and following untreated
patients from the beginning of the designated follow-up
period, resulting in disparate start times for treated vs.
untreated patients).6–8 Even when immortal time is correctly
classified, properly recording the follow-up time from
treatment initiation is also important to avoid bias. Earlier
studies have quantified the bias caused by misclassifying
immortal time.9,10 The bias can be severe. The immortal time
bias problem has been widely discussed in pharmacoepide-
miology and in some areas of medical research.5,9,11 It was
only recently noted as an issue in kidney disease research.12,13
With more and more observational data available for kidney
disease research, especially with release of Medicare Part D
data, the number of observational studies will likely increase
substantially, and therefore the kidney disease research
community should be aware of immortal time bias and
how to prevent it. Examples of immortal time bias can be
found in the nephrology literature. Although a systematic
review of the prevalence of immortal time bias in observa-
tional studies in nephrology is outside the scope of this study,
we briefly review three studies described in previous
editorials,12–14 in which such bias can reasonably be expected
to have resulted in spurious protective effects of exposure.
Hemmelgarn et al.8 analyzed the association of multi-
disciplinary care with all-cause mortality in a cohort of nearly
7000 elderly patients with chronic kidney disease (estimated
glomerular filtration rate o60ml/min per 1.73m2). Follow-
up for all patients began on the date of the first outpatient
serum creatinine measurement in the interval from 1 July
to 31 December 2001. Exposure was defined by care in
a multidisciplinary care clinic between 1 July 2001 and 31
December 2002. Herein lies the problem. For patients who
were identified as exposed to multidisciplinary care, it is
conceivable that this care began as much as 12–18 months
after the initial serum creatinine measurement that marked
the beginning of follow-up. Any accumulated time from the
initial serum creatinine measurement to the beginning of
multidisciplinary care necessarily precluded the occurrence of
death; hence, this time was ‘immortal.’ The adjusted hazard
ratio of all-cause mortality for multidisciplinary care vs. not
was 0.50 (95% confidence interval, 0.35–0.71); much of this
protective effect can be attributed to immortal time being
mistakenly assigned to the multidisciplinary care patients.
A proper analysis of the data might include a time-dependent
variable for multidisciplinary care in the Cox regression for
time to death, such that all patients were considered to be
unexposed to multidisciplinary care until the care actually
began. This analysis would effectively ‘reassign’ accumulated
time without death from multidisciplinary care to non-
multidisciplinary care, thereby attenuating the hazard ratio of
all-cause mortality to the null (i.e., hazard ratio¼ 1).
In another study of patients with predialysis chronic
kidney disease, Kovesdy et al.6 examined the association
of activated vitamin D treatment with all-cause mortality
(with censoring at the time of ESRD onset). The study cohort
included 520 men who received care at a Veterans Affairs
medical center; importantly, serum intact parathyroid
hormone (iPTH) was measured at least once for all included
patients before initiation of maintenance dialysis. Patients
with no record of activated vitamin D treatment between the
date of the initial iPTH measurement and 30 June 2005 were
classified as unexposed. For these patients, follow-up began
on the date of the initial iPTH measurement. Conversely,
patients with a record of activated vitamin D treatment in
this interval were classified as exposed. Follow-up for these
patients began on the date of the first vitamin D treatment.
As in the first example, the problem of immortal time lies
with the exposed patients. Specifically, all accumulated time
from the initial iPTH measurement to the first vitamin D
treatment was excluded from the analysis. This accumulated
time necessarily precluded the occurrence of death, and,
importantly, all of this time was coincident with the absence
of vitamin D treatment. Therefore, the analysis likely
overstated the risk of death in the absence of vitamin D
treatment, thereby producing a spurious protective effect of
treatment. Indeed, the unadjusted hazard ratio of all-cause
mortality for vitamin D treatment vs. not was 0.53
(0.37–0.77), but after proper attribution of accumulated unex-
posed time in patients who eventually received vitamin D,
the unadjusted hazard ratio was 0.78 (0.54–1.12).13 This
attenuation was unsurprising, given a median of 146 days
between initial iPTH measurement and the first vitamin D
treatment.
Finally, Jones et al.15 evaluated the association of kidney
transplant with all-cause mortality in a cohort of 253 ESRD
patients who underwent coronary angiography as part of
pretransplant evaluation. Follow-up for all patients began
on the date of the pretransplant evaluation. Patients who
subsequently underwent kidney transplant were considered
to be exposed, whereas patients who did not undergo
transplant were considered to be unexposed. Exposed
patients accumulated time between the dates of angiography
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Figure 1 | Illustration of immortal time. Only treated patients
who initiate treatment after the follow-up start time experience
immortal time.
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and transplant; this accumulated time precluded the occur-
rence of death. With this immortal time included in the
analysis, the adjusted hazard ratio of all-cause mortality
for transplant vs. not was 0.19; transplant was similarly
associated with lower risk of death in three strata defined by
severity of coronary artery disease. This estimated hazard
ratio was likely optimistic, because accumulated time
between angiography and transplant was inappropriately
attributed to the exposure, when in fact the time was
coincident with the absence of exposure. A proper analysis of
the data might include a time-dependent variable for
transplant in the Cox regression for time to death, such that
all patients who eventually underwent transplant were
considered to be unexposed until the transplant occurred.
An important commonality in these examples is the role
of study design in the induction of immortal time. Immortal
time is not a property of human biology; without knowledge
of the future, whether a patient will survive the next day or
month is always uncertain. Instead, immortal time is induced
by study design, insofar as treatment initiation may be used
to characterize patient history in the past (i.e., the time
before treatment initiation). In the examples given above,
differential definitions of follow-up initiation in exposed and
unexposed patients and misclassification of exposure likely
resulted in bias. Alternative analytical approaches in each
example would have eliminated whatever bias was attribut-
able to immortal time.
IMMORTAL TIME BIAS SIMULATIONS
Numerous types of bias that may invalidate estimates of
treatment effects can be encountered in observational studies.
For the purposes of this analysis, all types of bias other than
immortal time bias were assumed not to be present. In
particular, except in the Confounder Adjustment section
below, we assumed no confounding between treatment
assignment and prognostic factors, and we assumed that
censoring was independent of the outcome. To illustrate that
severe bias can be introduced by mishandling immortal time,
we performed simulations using two common time-to-event
distributions: the exponential and the Weibull. The expo-
nential distribution has a constant hazard 1/l, and Weibull
distribution has a time-varying hazard bl
 
t
l
 b1
, where t is
the time to event, and l and b are fixed parameters. For
Weibull distribution, when bo1, the hazard of event
decreases over time; when b41, the hazard increases; and
when b¼ 1, the hazard is a constant, which is the exponential
distribution. To allow for a large range of distributions,
different values were assigned to l and b for simulations
(see Appendix for details). For ease of illustration, we
assumed that the treatment had no effect on outcome.
For each set of parameter values, 1000 samples of size 10,000
were drawn.
The time-to-event analyses were conducted using four
methods of handling immortal time. In method 1, immortal
time was ignored and treated patients were followed up from
treatment initiation; in method 2, patients were considered as
treated during the entire immortal time period; in method 3,
patients were considered as not treated during the immortal
time period, and follow-up was restarted at treatment
initiation; and in method 4, treatment was parameterized
as a time-dependent variable. Table 1 shows three examples
that highlight how each method handles follow-up time in
time-to-event analysis with treated patients. In example 1,
patient A was diagnosed with a disease on 10 May 2005, and
started treatment immediately. Patient A was followed up to
31 December 2006, and experienced no event. No immortal
time occurred for patient A. In example 2, patient B was
diagnosed with the disease on 1 January 2005, started
treatment on 21 May 2005, and experienced an event on
15 July 2006. Immortal time for patient B occurred from
1 January 2005 to 21 May 2005. In example 3, patient C was
diagnosed with the disease on 10 March 2005, started
treatment on 2 April 2005, was followed up until the end of
the study date (31 December 2006), and experienced no
event. Figure 2 intuitively illustrates how patient B was
followed up with each method. Table 1 also illustrates how
the follow-up time was handled for untreated patients:
patient D was diagnosed with the disease on 1 June 2005,
never received treatment, and was followed up to 10 July
2006, with no event. There is no possibility of immortal time
for untreated patients. For treated patients with immortal
time, methods 2 and 4 set the follow-up clock to 0 at the
beginning of follow-up, but methods 1 and 3 reset the follow-
up clock to 0 at treatment initiation.
A Cox proportional hazards regression model was used to
assess the treatment effect for each sample for all four
methods. Hazard ratios (treatment vs. control) were used to
assess the treatment effect. Because we assumed no treatment
effect, the true hazard ratio is 1. If the estimated hazard ratio
was less than 1, the treatment effect was overestimated, and if
the estimated hazard ratio was greater than 1, the treatment
effect was underestimated. For each set of parameter values,
the mean, minimum, and maximum, and 25th and 75th
percentiles of estimated hazard ratios of the 1000 samples
were tabulated. As median values were essentially the same as
mean values, they are not displayed. In addition, the portion
of hazard ratio estimates that are statistically significantly
(Po0.05) different from 1 was calculated for each method.
The proportion of significant estimates of the hazard ratio
from a correct method should be approximately equal to 5%,
being consistent with type I error 0.05.
Tables 2 and 3 show the simulation results for the
exponential distribution and Weibull distribution, respec-
tively. For the exponential distribution (Table 2), which has
constant hazard, methods 1 and 2 always underestimated the
hazard ratio (treatment vs. control), and therefore over-
estimated the treatment effect. Method 1 underestimated the
hazard ratio by as much as 66% and method 2 by as much
as 88%. Methods 3 and 4 estimated the treatment effect
properly; most hazard ratio estimates were close to 1 and
about 5% of tests were statistically significant. For the
Weibull distribution (Table 3), which has time-varying
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hazard, method 2 always underestimated the hazard ratio,
by as much as 96%. Methods 1 and 3 also produced biased
estimates of the hazard ratio, either underestimating or
overestimating. Bias ranged from an underestimate of up
to 92% to an overestimate of up to 54% for method 1, and
an underestimate of up to 71% to an overestimate of up to
138% for method 3. Method 4 worked well for the hazard
ratio estimate; the estimates were close to 1, and on average
only 5.1% of the hazard ratio estimates were significantly
different (Po0.05) from 1.
INTUITIVE EXPLANATION OF SIMULATION RESULTS
Simulations showed that for events with constant hazard
(exponential survival time), methods 1 and 2 always over-
estimated treatment effect, but methods 3 and 4 worked well;
for events with time-varying hazard (Weibull survival time),
only method 4 produced unbiased estimates. These results
illustrate the direction and potential extent of bias that could
occur using different methods of handling immortal time.
We used a hazard ratio of 1 (no treatment effect) in our
examples, but the same bias issues apply if incorrect
methodology is applied in the presence of a treatment effect.
The direction of the bias illustrated by the simulation did
not randomly occur in the simulation, but is based on the
theoretical derivation. The theoretical proof for this is
beyond the scope of this article, but the concept can be
explained intuitively.
If the hazard is a constant, understanding that methods
1 and 2 always overestimate the treatment effect is easy. For
constant hazard events, the event rate or the hazard is
estimated by number of events divided by total follow-up
time. Method 1 can produce an unbiased estimate of the
event rate in the treatment group. Resetting the follow-up
clock does not affect the unbiased nature of the estimate
because of the memory-less property of exponential dis-
tribution. However, method 1 overestimates the event rate for
the control group because immortal time should be included
in the denominator of the event rate calculation for the
control group, but is not. Therefore, method 1 will under-
estimate the rate ratio/hazard ratio of treatment vs. control;
that is, it overestimates the treatment effect. Similarly,
method 2 underestimates the event rate in the treatment
group and overestimates the event rate in the control group,
Table 1 | Examples of how methods of handling immortal time affect how patients are followed up in analysis
Follow-up period Follow-up time
Method Patient Start date End date Start time End time Length of follow-up (days) Treatment Event
Treated patients
Method 1
A 10/5/2005 31/12/2006 0 432 432 1 0
B 21/5/2005 15/7/2006 0 421 421 1 1
C 2/4/2005 31/12/2006 0 639 639 1 0
Method 2
A 10/5/2005 31/12/2006 0 432 432 1 0
B 1/1/2005 15/7/2006 0 561 561 1 1
C 10/3/2005 31/12/2006 0 662 662 1 0
Method 3
A 10/5/2005 31/12/2006 0 432 432 1 0
B 1/1/2005 20/5/2005 0 140 140 0 0
B 21/5/2005 15/7/2006 0 421 421 1 1
C 10/3/2005 1/4/2005 0 23 23 0 0
C 2/4/2005 31/12/2006 0 639 639 1 0
Method 4
A 10/5/2005 31/12/2006 0 432 432 1 0
B 1/1/2005 20/5/2005 0 140 140 0 0
B 21/5/2005 15/7/2006 141 561 421 1 1
C 10/3/2005 1/4/2005 0 23 23 0 0
C 2/4/2005 31/12/2006 24 662 639 1 0
Untreated patient
D 1/6/2005 10/7/2006 0 407 407 0 0
Time
0
1/1/2005
1/1/2005
1/1/2005
Diagnosis date
1/1/2005
Treatment start date
Treatment period
Nontreatment period Event
Method 1
Method 2
Method 3
Method 4
21/5/2005
21/5/2005
21/5/2005
21/5/2005
21/5/2005
21/5/2005
15/7/2006
15/7/2006
15/7/2006
15/7/2006
15/7/2006
Death date
Censoring
Figure 2 | Follow-up of patient B (in Table 1) with the four
methods for handling immortal time. Method 1: ignore the
immortal time period. Method 2: consider the immortal time
period as treated. Method 3: consider the immortal time period as
untreated and restart the patient clock to 0 at treatment initiation.
Method 4: parameterize the treatment as time varying.
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because immortal time should be included in the denomi-
nator of the calculation for the control group, but is instead
mistakenly included in the denominator of the calculation
for the treatment group. Therefore, method 2 always
produces larger bias than method 1. Method 4 appropriately
attributes immortal time and incorporates the time-depen-
dent feature of treatment; therefore, it gives unbiased
estimates of treatment effect. Method 3 classifies immortal
time correctly, but it does not incorporate the time-
dependent feature of treatment. It gives unbiased estimates
of treatment effect because of the memory-less property of
exponential distribution. The plot of cumulative hazard
(log survival) vs. time can be used to determine whether
the hazard is constant. If this plot is a straight line, the hazard
Table 2 | Simulation results (hazard ratios) for exponential distributions
Method Mean Minimum Maximum 25th Percentile 75th Percentile Percent significanta
Example 1–1
Method 1 0.4621 0.4109 0.5073 0.4535 0.4714 100.0
Method 2 0.1824 0.1490 0.2032 0.1782 0.1865 100.0
Method 3 1.0004 0.9045 1.0956 0.9812 1.0190 5.1
Method 4 1.0012 0.8638 1.1286 0.9763 1.0271 5.7
Example 1–2
Method 1 0.5484 0.5047 0.5956 0.5385 0.5577 100.0
Method 2 0.2197 0.1984 0.2408 0.2154 0.2241 100.0
Method 3 1.0009 0.9190 1.0830 0.9835 1.0169 3.9
Method 4 1.0009 0.8928 1.0967 0.9793 1.0233 4.6
Example 1–3
Method 1 0.6307 0.5819 0.6821 0.6193 0.6417 100.0
Method 2 0.2587 0.2401 0.2830 0.2537 0.2635 100.0
Method 3 1.0002 0.9301 1.0821 0.9828 1.0167 4.7
Method 4 0.9999 0.9005 1.1019 0.9780 1.0215 4.6
Example 2–1
Method 1 0.3815 0.3372 0.4100 0.3751 0.3879 100.0
Method 2 0.1442 0.1196 0.1588 0.1414 0.1473 100.0
Method 3 1.0005 0.9253 1.0793 0.9841 1.0173 5.8
Method 4 1.0007 0.9007 1.1050 0.9801 1.0209 5.1
Example 2–2
Method 1 0.4614 0.4259 0.4992 0.4530 0.4695 100.0
Method 2 0.1800 0.1547 0.1978 0.1763 0.1838 100.0
Method 3 1.0017 0.9217 1.0893 0.9835 1.0190 6.6
Method 4 1.0020 0.9028 1.1213 0.9783 1.0253 6.3
Example 2–3
Method 1 0.5464 0.5007 0.5950 0.5361 0.5559 100.0
Method 2 0.2189 0.2003 0.2437 0.2142 0.2237 100.0
Method 3 1.0009 0.9026 1.0895 0.9822 1.0188 6.0
Method 4 1.0009 0.8680 1.1351 0.9767 1.0235 6.2
Example 3–1
Method 1 0.4906 0.4425 0.5420 0.4803 0.5011 100.0
Method 2 0.1950 0.1701 0.2231 0.1904 0.1998 100.0
Method 3 1.0022 0.8967 1.1104 0.9819 1.0220 5.9
Method 4 1.0034 0.8649 1.1406 0.9784 1.0281 4.9
Example 3–2
Method 1 0.5333 0.4871 0.5851 0.5224 0.5433 100.0
Method 2 0.2132 0.1892 0.2437 0.2086 0.2178 100.0
Method 3 1.0000 0.9166 1.0953 0.9798 1.0185 5.8
Method 4 0.9992 0.9007 1.1178 0.9742 1.0223 5.3
Example 3–3
Method 1 0.5511 0.5079 0.6029 0.5411 0.5605 100.0
Method 2 0.2208 0.2021 0.2450 0.2160 0.2254 100.0
Method 3 1.0000 0.9137 1.1000 0.9826 1.0166 4.6
Method 4 0.9994 0.9011 1.0998 0.9777 1.0197 4.7
Note: Minimum and maximum values illustrate the range of potential bias seen in our simulation using 1000 samples. More extreme or less extreme values could have been
seen with a larger or smaller number of simulations, respectively.
aStatistically significant hazard ratios with type I error 0.05.
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is constant; otherwise, the hazard is not constant. If the
results (hazard ratios) of analyses using methods 3 and 4 are
very different from each other, this is an important indicator
that the hazard is not constant.
For time-varying hazard events, method 2 always over-
estimates the treatment effect because it subtracts immortal
time, in which no events occur, from the control group and
adds that time to the treatment group. Methods 1 and 3 can
overestimate or underestimate the treatment effect, depend-
ing on how the hazard changes over time and the distribution
of immortal time. When the hazard monotonically decreases
over time, both methods always overestimate the treatment
effect. When the hazard monotonically increases, method 3
underestimates the treatment effect. Method 1 may still
Table 3 | Simulation results (hazard ratios) for Weibull distributions
Method Mean Minimum Maximum 25th Percentile 75th Percentile Percent significanta
Example 1–1
Method 1 0.1105 0.0839 0.1222 0.1080 0.1130 100.0
Method 2 0.0618 0.0435 0.0689 0.0603 0.0634 100.0
Method 3 0.3377 0.3043 0.3788 0.3307 0.3449 100.0
Method 4 1.0006 0.8473 1.1506 0.9695 1.0305 4.7
Example 1–2
Method 1 0.1534 0.1381 0.1690 0.1500 0.1570 100.0
Method 2 0.0887 0.0781 0.0991 0.0865 0.0909 100.0
Method 3 0.3401 0.3121 0.3758 0.3330 0.3474 100.0
Method 4 1.0032 0.8494 1.1350 0.9700 1.0355 4.4
Example 1–3
Method 1 0.2017 0.1778 0.2451 0.1966 0.2067 100.0
Method 2 0.1211 0.1065 0.1772 0.1174 0.1243 100.0
Method 3 0.3337 0.2940 0.3733 0.3254 0.3419 100.0
Method 4 1.0043 0.8378 1.1999 0.9671 1.0440 4.7
Example 2–1
Method 1 0.1986 0.1579 0.2240 0.1945 0.2029 100.0
Method 2 0.1016 0.0727 0.1150 0.0991 0.1042 100.0
Method 3 0.5003 0.4553 0.5521 0.4905 0.5099 100.0
Method 4 1.0022 0.8656 1.1323 0.9723 1.0306 5.9
Example 2–2
Method 1 0.2638 0.2169 0.2891 0.2590 0.2693 100.0
Method 2 0.1387 0.1083 0.1548 0.1357 0.1420 100.0
Method 3 0.5007 0.4461 0.5428 0.4918 0.5105 100.0
Method 4 0.9993 0.8578 1.1327 0.9712 1.0273 6.2
Example 2–3
Method 1 0.2864 0.2560 0.3145 0.2804 0.2923 100.0
Method 2 0.1519 0.1258 0.1685 0.1485 0.1552 100.0
Method 3 0.5001 0.4586 0.5435 0.4905 0.5091 100.0
Method 4 1.0011 0.8856 1.1488 0.9733 1.0272 4.6
Example 3–1
Method 1 1.0787 0.9850 1.1652 1.0586 1.0985 77.4
Method 2 0.2731 0.2444 0.3104 0.2666 0.2791 100.0
Method 3 2.1675 1.9648 2.3774 2.1251 2.2091 100.0
Method 4 1.0009 0.8732 1.1265 0.9767 1.0232 5.2
Example 3–2
Method 1 1.2236 1.1373 1.3369 1.2037 1.2427 100.0
Method 2 0.3286 0.3015 0.4163 0.3227 0.3346 100.0
Method 3 2.1037 1.9543 2.2605 2.0648 2.1395 100.0
Method 4 1.0001 0.9178 1.0886 0.9809 1.0199 3.3
Example 3–3
Method 1 1.3611 1.2447 1.5360 1.3371 1.3852 100.0
Method 2 0.3837 0.3421 0.5015 0.3762 0.3903 100.0
Method 3 2.0620 1.8643 2.2485 2.0219 2.1023 100.0
Method 4 0.9993 0.9171 1.0978 0.9795 1.0184 6.7
Note: Minimum and maximum values illustrate the range of potential bias seen in our simulation using 1000 samples. More extreme or less extreme values could have been
seen with a larger or smaller number of simulations, respectively.
aStatistically significant hazard ratios with type I error 0.05.
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overestimate the treatment effect when the hazard mono-
tonically increases slowly, and change to favor the control
group when the hazard increases quickly. This occurs because
in methods 1 and 3 the follow-up clock is reset to 0 at
treatment initiation. This forces a comparison between a time
of early risk in the control group and a time of late risk in the
treated group. For a decreasing hazard, the later the time the
lower the risk; therefore, the methods compare a lower-risk
period in the treatment group with a higher-risk period in
the control group, thus overestimating the treatment effect.
Conversely, for an increasing hazard, the later the time the
higher the risk; therefore, method 3 underestimates the
treatment effect. This also explains why method 3 produces
unbiased estimates when the hazard is constant. Method 1
may still overestimate the treatment effect when the hazard
increases slowly because the hazard for the control group is
overestimated because of the event-free immortal time, which
is part of the control, being ignored. This overestimate may
absorb the early and late risk difference. Thus, whether
method 1 overestimates or underestimates the treatment
effect is determined by how quickly the hazard increases, the
distribution of immortal time, and the proportion of patients
in the treatment group.
Figure 3 displays the hazard functions of three Weibull
distributions in simulation. Hazards are decreased in distri-
butions Weibull(1500, 0.33) and Weibull(500, 0.5), and
increased in distribution Weibull(1500, 2), where the first
parameter in the distribution is l and the second is b (i.e.,
l¼ 1500 and b¼ 0.33 in Weibul(1500, 0.33)). Therefore,
methods 1 and 3 always overestimate the treatment effect for
Weibull(1500, 0.33) and Weibull(500, 0.5), and under-
estimate the treatment effect for Weibull(1500, 2). To deter-
mine whether a hazard monotonically decreases or increases
over time from data, the cumulative hazard (log survival)
vs. time can be plotted for the control group. If the
cumulative hazard plot is concave, the hazard decreases over
time and if the cumulative hazard plot is convex, the hazard
increases. Similar to the constant hazard situation, method 4
appropriately attributes immortal time and incorporates the
treatment change based on the initial follow-up time, and
therefore produces an unbiased estimate. Method 4 always
produces an unbiased estimate because it incorporates the
nature of the data.
NONPARAMETRIC COMPARISON FOR UNADJUSTED
ANALYSIS
The Kaplan–Meier plot is the most widely used method to
intuitively compare treatment groups. However, it may not
be valid when the treatment is time dependent, because it
cannot incorporate the time-dependent nature of the
treatment. For treatment, the time to event either starts
from the beginning of follow-up, considering the immortal
time as treated, or is (re)set to 0 at treatment initiation. Thus,
results from the Kaplan–Meier plots correspond to methods
1, 2, or 3, depending on how the immortal time is handled.
Similarly, the nonparametric testing methods for treatment
effect comparison, such as the log-rank test or the Wilcoxon
test, may also be unable to produce valid results. If the hazard
is a constant, the Kaplan–Meier plot and the nonparametric
test corresponding to method 3 will be valid. If the hazard is
time varying, the time-varying Cox model with treatment as
the only independent variable can yield a valid result for
unadjusted treatment comparison, but the survival curve
cannot be easily produced for intuitive comparison.
BASELINE COMPARISON
Time dependency of treatment not only increases the
complexity of treatment effect comparison, but also increases
the difficulty of patient characteristic comparison among
treatment groups. For never-treated patients, only baseline
characteristics can be considered. But for treated patients,
characteristics can be measured at two time points, at
baseline and at the time of change from control to treatment.
Neither is a good choice for comparison with baseline
characteristics of the control group. We suggest reporting
patient characteristics at baseline for all patients, never-
treated patients, and treated patients, respectively, and
reporting patient characteristics at treatment initiation for
treated patients. No comparison can directly differentiate
between treatment and control groups as in a prospective
study in which treatment is initiated at the beginning of the
study. However, comparing patient characteristics at different
time points can help answer specific questions. For example,
by comparing treatment group characteristics at baseline and
at treatment initiation, researchers may see a change that led
to treatment initiation. By comparing baseline characteristics
in control and treatment groups, researchers may determine
reasons that some patients were treated and others were not.
Statistical testing of patient characteristic differences among
groups also becomes complex because some patients are in
multiple groups.
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Figure 3 |Plots of hazard functions of the Weibull
distributions in the simulation. The hazards of Weibull(1500,
0.33) and Weibull(500, 0.5) decrease over time, and the hazard of
Weibull(1500, 2) increases over time.
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CONFOUNDER ADJUSTMENT
In our simulations, we assumed that no confounders
existed, and method 4, the time-varying method, is the only
method that can produce unbiased estimates of treatment
effect. However, in most observational studies, adjustments
must be made for confounders. With confounders, the
time-varying method can still obtain valid estimates of
treatment effect, because it can incorporate the time-
dependent nature of treatment. When all confounders are
time invariant, one can simply adjust for baseline values of
the confounders. If time-dependent confounders are present
and can be measured and dated, they can be incorpo-
rated into the time-varying model if they are exogenous to
the analysis; that is, values are not influenced by the treat-
ment. If time-varying confounders are not exogenous, more
advanced methods, such as marginal structural modeling,14,16
should be used. Matched cohort study is another choice (see
next section).
FOLLOW-UP STARTING TIME
The above discussions are based on the assumption that the
follow-up start time is meaningful; that is, disease status for
all patients was the same at the start of follow-up and all
patients are eligible for treatment, and thus the hazard is the
same for all patients at the same time, controlling for all other
factors. Unless the hazard is constant, this is important.
Usually, disease onset can be considered a meaningful start
time for follow-up if all patients are at the same stage of the
disease at that point. If the analysis is for a prevalent cohort,
disease duration (time from disease onset to the start of
follow-up) should be assessed carefully, if data are available. If
the distribution of disease duration is highly related to
treatment or confounders, the analysis should incorporate
the disease duration. If the duration is a proportional factor,
the disease duration can be adjusted through the model.
Otherwise, a stratified analysis is necessary. Regardless of the
method used, the results should be reported with appropriate
cautionary notes.
Another recommended method for analysis with time-
dependent treatment is matched cohort analysis,12,17 in
which each treated patient is followed up from the treatment
start time with a matched control with the same disease
duration. However, caution is required here as well; an
incident analysis with time-dependent treatment may inad-
vertently become a prevalent analysis after matching for
disease duration, possibly resulting in an answer to a
question different from the question a study originally
sought to address.
AN EXAMPLE FROM ACTUAL PATIENT DATA
We used data from DaVita, linked with the Centers for
Medicare & Medicaid Services ESRD database, in this
example. Data included all Medicare hemodialysis patients
in DaVita facilities alive on 1 August 2004, with information
on dates of death, hospitalization, and initiation and
discontinuation of a common medication used to manage
bone and mineral disorders in dialysis patients. Specific
details about the medication are omitted, as our goal is only
to illustrate differences in treatment effect estimates by four
methods. To simplify this example, we calculated the hazard
ratio for time to first hospitalization, without considering
patient characteristics and other bias sources. Table 4 shows
estimates of the hazard ratio for treatment effect on first
hospitalization for DaVita Medicare hemodialysis patients for
each of the four methods. Method 4 shows no treatment
effect on first hospitalization, but methods 1, 2, and 3 show
significant protective treatment effects. The hazard ratio
estimate using method 2 was 62% lower than the hazard
ratio estimate using method 4. Methods 3 and 4 produced
very different results, an indicator that the hazard of first
hospitalization was nonconstant. Therefore, method 4 is
likely the best analytical approach for these data. Figure 4
shows the Kaplan–Meier plots of no hospitalization prob-
abilities for treatment, with follow-up time reset to 0 at
treatment initiation, and two controls defined using different
approaches. The first approach ignores immortal time and
the second classifies immortal time as control. The
comparison between treatment and control approach 1
corresponds to method 1, and the comparison between
treatment and control approach 2 corresponds to method 3.
The Kaplan–Meier plots appear to show that treatment
produced better results than the controls. The log-rank
test showed that the difference in treatment effect was
statistically significant (Po0.0001 for treatment vs. control
for the first and the second approaches). Because a prevalent
cohort was used in this analysis, we also conducted an
analysis stratified by disease duration defined by the time
from dialysis initiation to 1 August 2004. The results were
very close to results without considering disease duration
(Table 4).
Table 4 | Unadjusted hazard ratios of treatment vs. no treatment for first hospitalization among hemodialysis patients in the
DaVita data set, 1 August 2004, unstratified and stratified by duration of disease
Unstratified analysis Stratified analysis
Method Hazard ratio Confidence interval P-value Hazard ratio Confidence interval P-value
Method 1 0.62 0.59–0.65 o0.0001 0.61 0.58–0.64 o0.0001
Method 2 0.38 0.36–0.39 o0.0001 0.37 0.35–0.39 o0.0001
Method 3 0.75 0.71–0.78 o0.0001 0.75 0.71–0.78 o0.0001
Method 4 0.98 0.94–1.04 0.53 0.98 0.93–1.03 0.49
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DISCUSSION
Our simulation illustrates that careful consideration of
methodology is needed in analyzing effects of time-
dependent treatment in observational studies. Depending
on the methodology, estimated treatment effects can be
substantially biased. For events with constant hazard,
methods 1 and 2 always overestimated treatment effect, but
methods 3 and 4 worked well. For events with time-varying
hazard, only method 4 yielded an unbiased result. The
nonparametric methods yielded results similar to results
from methods 1, 2, or 3, depending on how immortal time
was handled. Differences in treatment effect estimates using
actual patient data, including apparent biases with methods
1, 2, and 3, were consistent with simulation results; the
nonparametric methods also gave incorrect conclusions for
this analysis. This underscores that methodology that does
not account appropriately for immortal time can result in
significant bias in observational studies of time-dependent
treatments.
Exponential and Weibull distributions were used for
simulation examples in this study because they are the most
widely used distributions for describing time to event.
Although exponential distribution is a special case of Weibull,
we considered it separately because it is often used in medical
research. For example, using Poisson regression to model
event rates implicitly assumes that time to event follows an
exponential distribution. The Poisson model is used
frequently in event rate analysis.18–21
We chose the four methods for demonstration because
methods 1 and 2 are used often, and method 4 is the
proper method for conducting time-dependent treatment
analysis and is used with increasing frequency in medical
research.22–24 The Kaplan–Meier method, the log-rank test,
and the other nonparametric methods for survival analysis
are examples of method 3, when immortal time is classified
correctly. These methods (re)set the treatment initiation time
as time 0.
The time-dependent Cox model is the correct model for
use with time-dependent treatment. However, the immortal
time problem is far too complex to be solved by simply using
a statistical model correctly. Issues include awareness of
immortal time, correct understanding of the data (incident
or prevalent cohort, time-varying or time invariant con-
founders, etc.), and the features of the risk (constant hazard
or time-varying hazard) of the study outcome.
In summary, our review and simulation describe the
immortal time problem using exponential and Weibull
distributions as examples. However, real-world data are often
complex. The hazard may be neither constant nor monotone.
However, the time-dependent feature of treatment must be
properly incorporated to avoid possible bias irrespective of
the shape of the hazard function. In simulations, we assumed
no treatment effect. The degree of estimate bias may be
different when the treatment is different from the control,
but all discussions of issues related to immortal time can be
applied to analyses with treatment effect.
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APPENDIX
DATA SIMULATION
In addition to time-to-event distributions, distributions
for time to censoring and time to treatment initiation
were also considered. We assumed that time to censoring
followed an exponential distribution, time to treatment
initiation followed a uniform distribution, and all three
distributions (time to event, time to censoring, and time
to treatment initiation) were mutually independent. Maxi-
mum follow-up time was also specified for each example.
Different values were specified for the distributional
parameters and maximum follow-up time to yield a large
range of distribution and to induce different proportions
of treatment and censoring. Follow-up ended at event
occurrence, censoring, or study end, whichever came first.
For each simulated patient, if treatment initiation occurred
after the end of follow-up, then treatment did not
occur for that patient during the study. In simulation, nine
sets of parameter values for each of the exponential
distribution and Weibull distribution were executed. For
each set of parameter values, 1000 samples of size 10,000
were drawn.
Parameters for all simulated distributionsa
Distribution k For time to event b For time to event b For treatmentb k For time to censoring Longest follow-up
Exponential
Example 1–1 500 600 1000 800
Example 1–2 500 1000 1500 3000
Example 1–3 500 1500 2000 1500
Example 2–1 800 1000 5000 2000
Example 2–2 800 1200 3000 2000
Example 2–3 800 1500 2000 1500
Example 3–1 1200 1500 2000 1500
Example 3–2 1200 2000 2500 2000
Example 3–3 1200 2500 4000 3000
Weibull
Example 1–1 1500 0.33 1000 5000 3500
Example 1–2 1500 0.33 1500 3000 2500
Example 1–3 1500 0.33 2500 2000 1500
Example 2–1 500 0.50 500 1500 1000
Example 2–2 500 0.50 1000 1500 1300
Example 2–3 500 0.50 1500 2000 1500
Example 3–1 1500 2.00 1500 2000 1500
Example 3–2 1500 2.00 2000 3000 2000
Example 3–3 1500 2.00 2500 3000 2000
aAssuming day is the unit of follow-up.
bAssuming the time to treatment follows a uniform distribution on time interval (0,b).
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